ClinicalTrials.gg
CompletedNCT02267343Updated May 3, 2024

Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

A Phase 3 interventional study of ONO-4538 and Placebo in Gastric Cancer, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 49 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies testing nivolumab in Stomach Neoplasms — 6 open to participants now, 13 under way, 2 of them phase 3. Nivolumab · Stomach Neoplasms.

Enrollment
6th of 30
493 · median 49
Started
2014
the only one that year
Phase 3
6 of 30
1 open now
Registered
1st of 30
by date
Lead sponsor
3 of 30
Ono Pharmaceutical Co. Ltd

Among the 30 studies testing nivolumab in Stomach Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2014, is one of 6 in phase 3, and was the 1st registered.

Stomach Neoplasms

3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 30 studies testing nivolumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing nivolumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men \& women ≥20 years of age
  • Unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer)
  • confirmed adenocarcinoma
  • to or intolerant of standard therapy
  • Performance Status score 0 or 1
  • A of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Current or past history of severe to any other antibody products
  • Patients with multiple primary cancers
  • Patients with any in the brain or meninx that is symptomatic or requires treatment
  • Patients with active, known or suspected disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    ONO-4538 Arm

    ONO-4538 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

    Drug: ONO-4538

  • Placebo comparator
    Placebo Arm

    Placebo intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: Up to study completion (estimated time frame: 30 months), every 2 weeks in principle

Secondary outcomes

  1. Progression-free survival

    Time frame: Up to study completion (estimated time frame: 30 months), every 2 weeks in principle

  2. Objective response rate

    Time frame: Up to study completion (estimated time frame: 30 months), every 6 weeks in principle

  3. Duration of response

    Time frame: Up to study completion (estimated time frame: 30 months), every 6 weeks in principle

  4. Safety will be analyzed through the incidence of adverse events, serious adverse events

    Time frame: Continuously throughout study treatment and up to 28 days from last dose

  5. Safety will be analyzed through the incidence of laboratory abnormalities

    Time frame: Continuously throughout study treatment and up to 28 days from last dose

07

Study locations

49 sites
  • Aichi Clinical Site
    Nagoya, Aichi 464-8681, Japan
  • Aomori Clinical Site
    Misawa, Aomori 033-0022, Japan
  • Ehime Clinical Site
    Matsuyama, Ehime 791-0280, Japan
  • Hokkaido Clinical Site
    Sapporo, Hokkaido 060-8648, Japan
  • Hyogo Clinical Site
    Akashi, Hyogo 673-8558, Japan
  • Hyogo Clinical Site
    Kobe, Hyogo 650-0047, Japan
  • Ishikawa Clinical Site
    Kanazawa, Ishikawa 920-8641, Japan
  • Kanagawa Clinical Site
    Kawasaki, Kanagawa 216-8511, Japan
  • Kanagawa Clinical Site
    Sagamihara, Kanagawa 252-0375, Japan
  • Kanagawa Clinical Site
    Yokohama, Kanagawa 241-8515, Japan
  • Nagano Clinical Site
    Saku, Nagano 385-0051, Japan
  • Osaka Clinical Site
    Osakasayama, Osaka 589-8511, Japan
  • Osaka Clinical Site
    Suita, Osaka 565-0871, Japan
  • Osaka Clinical Site
    Takatsuki, Osaka 569-8686, Japan
  • Saitama Clinical Site
    Kitaadachi, Saitama 362-0806, Japan
  • Shizuoka Clinical Site
    Sunto-gun, Shizuoka 411-8777, Japan
  • Tochigi Clinical Site
    Shimotsuke, Tochigi 329-0498, Japan
  • Tokyo Clinical Site
    Bunkyo-ku, Tokyo 113-8677, Japan
  • Tokyo Clinical Site
    Chuo-ku, Tokyo 104-0045, Japan
  • Tokyo Clinical Site
    Koto-ku, Tokyo 135-8550, Japan
  • Tokyo Clinical Site
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Chiba Clinical Site
    Chiba, 260-8717, Japan
  • Fukuoka Clinical Site
    Fukuoka, 811-1395, Japan
  • Fukuoka Clinical Site
    Fukuoka, 812-8582, Japan
  • Gifu Clinical Site
    Gifu, 501-1194, Japan
  • Hiroshima Clinical Site
    Hiroshima, 730-8518, Japan
  • Osaka Clinical Site
    Osaka, 537-8511, Japan
  • Shizuoka Clinical Site
    Shizuoka, 420-8527, Japan
  • Busan-si Clinical Site
    Busan-si, 602-715, Korea, Republic of
  • Daegu Clinical Site
    Daegu, 702-210, Korea, Republic of
  • Gyeonggi-Do Clinical Site
    Gyeonggi-Do, 410-769, Korea, Republic of
  • Gyeonggi-Do Clinical Site
    Gyeonggi-Do, 463-707, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 110-744, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 120-752, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 135-710, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 135-720, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 136-705, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 137-701, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 138-736, Korea, Republic of
  • Seoul Clinical Site
    Seoul, 152-703, Korea, Republic of
  • Kaohsiung Clinical Site
    Kaohsiung, 807, Taiwan
  • Kaohsiung Clinical Site
    Kaohsiung, 833, Taiwan
  • Taichung Clinical Site
    Taichung, 40447, Taiwan
  • Tainan Clinical Site
    Tainan, 704, Taiwan
  • Taipei Clinical Site
    Taipei, 10002, Taiwan
  • Taipei Clinical Site
    Taipei, 112, Taiwan
  • Taipei Clinical Site
    Taipei, 114, Taiwan
  • Taipei Clinical Site
    Taipei, 116, Taiwan
  • Taoyuan Clinical Site
    Taoyuan, 333, Taiwan
08

References and documents

Publications

  • Kang YK, Reck M, Nghiem P, Feng Y, Plautz G, Kim HR, Owonikoko TK, Boku N, Chen LT, Lei M, Chang H, Lin WH, Roy A, Bello A, Sheng J. Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. J Immunother Cancer. 2022 Apr;10(4):e004273. doi: 10.1136/jitc-2021-004273. PubMed 35383114 ↗
  • Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. PubMed 28993052 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Aug 2016, 22 months.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 22 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2014
First posted
Oct 17, 2014
StartActual
Oct 2014
Primary completionActual
Aug 2016
CompletionActual
Jan 2021
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02267343
Responsible party
Sponsor
First posted
Oct 17, 2014
Start date
Oct 2014
Primary completion
Aug 2016
Completion
Jan 2021
Last update
May 3, 2024

Study contacts

Mitsunobu Tanimoto
study director · Ono Pharmaceutical Co. Ltd

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion